GLCE

Across TCGA pan-cancer cohorts, GLCE mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GLCE data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GLCE mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GLCE expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LSCC, PDAC, and GBM are the cancer types where GLCE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	0.686	1.000	.015	10	view →
PDAC	DFS	Quartile	III,IV	0.815	0.220	.004	8	view →
GBM	DFS	Median	All	0.626	0.796	.005	6	view →
UCEC	OS	Median	All	0.970	0.836	.012	4	view →
HNSC	OS	Quartile	IV	0.624	0.887	.030	3	view →
LUAD	OS	Quartile	II,III,IV	0.377	0.681	.034	2	view →
CCRCC	DFS	Tertile	All	0.795	0.611	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GLCE–LSCC (OS)

Open the LSCC breakdown →